by Mike Regan | Jun 6, 2022 | Company Analysis
This is a follow-up to the January 16, 2022 article analyzing the contractually mandated dilution due to existing contracts at the Parent Company, which noted the potential signaling by the recipients. The 1Q22 10Q answers that question: This article is for...
by Mike Regan | Jun 6, 2022 | Comp Table & Market Commentary, Company Analysis
You may have heard about the roller coaster direct listing (NOT an IPO) of Bright Green Corp (BGXX), a company that plans to cultivate cannabis for pharmaceutical research under a license from the DEA. This has little read through to the rest of the US cannabis...
by Mike Regan | Jun 6, 2022 | Comp Table & Market Commentary
May Review of Multiples: The comp table has been updated for 1Q22 earnings and can be accessed by Premium Members in real time. [Download not found] May Review of Multiples: Since March 31, the US plant touching operators on my comp table have on average (using the...
by Mike Regan | Jun 2, 2022 | Comp Table & Market Commentary, Company Analysis, Extract, Free, In the News, Macro, Podcast, Regional Data
Thanks to Rena Sherbill of Seeking Alpha’s Cannabis Investing Podcast for interviewing Mike and thanks to Colin Ferrian for joining our chat and getting the band back together for a one-off conversation. To quote the summary and transcript (available here) of...
by Mike Regan | Apr 29, 2022 | Company Analysis
Agrify’s 2021 Proxy came out this morning, and there is more information regarding the ownership of the largest customer (as detailed in this post on 4/1/21), as well as the share authorization. This also includes the takeaways from Benzinga, insights into the new...
